



ASX Announcement

For immediate release

27 January 2021

Resignation of Director

CSL Limited (ASX:CSL; USOTC:CSLLY) advises that the CSL Board of Directors has regretfully, but with mutual agreement, accepted Mr. Pascal Soriot's resignation from his position of Non-Executive Director, effective 1 February 2021.

Mr Soriot's departure from the Board was mutually agreed with Mr Soriot, Chief Executive Officer of AstraZeneca PLC. He has resigned to avoid any potential future conflict of strategic interest between CSL and AstraZeneca that may arise due to the acquisition of Alexion by AstraZeneca. The acquisition, announced on 12 December 2020, is subject to a number of closing conditions that have not yet been satisfied.

CSL's Chair, Dr Brian McNamee AO said "Whilst Pascal has only served for a short time as a Non-Executive Director of CSL, he made a strong contribution and become a valued member of the Board. CSL is regretful that Pascal's tenure has come to an early close. We look forward to maintaining our ongoing relationship as CSL continues to work closely with AstraZeneca on the critically important COVID-19 vaccine project for the benefit of Australians. On behalf of the CSL Board I thank Pascal for all his work and for his continued relationship with CSL through the vaccine efforts".

FURTHER INFORMATION

For further information, please contact:

Investors:

Mark Dehring
Head of Investor Relations
CSL Limited
Telephone: +613 9389 3407
Email: mark.dehring@csl.com.au

Media:

Christina Hickie
Senior Manager, Communications
CSL Limited
+61 429 609 762
Email: christina.hickie@csl.com.au